We consider that creating HCC prognostic schemas that include tumoral markers (such as AFP) can increase the predictive accuracy while optimizing patient selection for different therapies, thus improving the clinical benefit of a chosen therapeutic measure. Here, AFP is linked to hepatocellular carcinoma.